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Background: The lumbar transversus abdominis plane (TAP) block has become an optional part of multimodal
analgesia following several abdominal surgeries. There remains a lack of consensus regarding the extent of
dermatomal blockade following lumber TAP block, as well as the optimal local anesthetic volumes and concentrations.
The objectives of this pilot trial were to assess the feasibility of conducting a similar full-scale trial and gather information
on relevant clinical outcomes, namely whether greater local anesthetic volumes would lead to more cephalad
dermatomal blockade.
Methods: The study was a prospective, double-blinded pilot randomized controlled trial (RCT) with three arms,
each representing different local anesthetic volumes: 20 ml 0.5% ropivacaine, 30 ml 0.33% ropivacaine, and 40 ml
0.25% ropivacaine. We planned to recruit 30 females undergoing total abdominal hysterectomy for non-malignant
pathology, who would then receive bilateral ultrasound-guided midaxillary TAP blocks at the completion of surgery.
Randomized patients would be followed for 48 h post-block and would receive multimodal analgesia. The primary
outcomes were measurements of patient recruitment and safety, to inform the feasibility of a larger trial. The
main secondary outcome was the clinically pertinent endpoint of dermatomal blockade, which was assessed by
loss of sensation to ice and pinprick.
Results: Our target sample size was reached in 8 months, and the recruitment rate was 52% (31/60). A total of 58
TAP blocks were performed among 29 patients. All but one of the patients who received interventions were
successfully followed and assessed up to 48 h. No patient safety-related adverse events were reported during the
study period. The mean highest dermatome blocked in each group at any time point was T8. The 20 ml 0.5%
ropivacaine group achieved a T9–L1 block that lasted for 48 h. The 30 ml 0.33% ropivacaine group had a sensory
block from T9–L1 that regressed to T10–T12 between 24 and 48 h. The 40 ml 0.25% ropivacaine group reported
an initial sensory block from T9–T12 that regressed by 24 h to include only the T12 dermatome.
Conclusions: This pilot study demonstrated that the study design is feasible and safe to be carried to a full-scale
RCT. The preliminary clinical findings showed that increasing the volume, while maintaining a constant dose, of
local anesthetic does not appear to extend the height of dermatomal blockade following midaxillary TAP block.
This finding needs to be confirmed in future studies.
Trial registration: ClinicalTrials.gov registration is: NCT01307215.
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An important component of pain after abdominal surgery
is derived from the incision itself. The lumbar transversus
abdominis plane (TAP) block has become a tool for the
multimodal perioperative pain management for several
surgical procedures, including total abdominal hyster-
ectomy [1].
The initial technique was described by Rafi [2] in 2001
as a blind technique using surface landmarks at the
Petit triangle and was further developed and tested by
McDonnell [3-5]. Soon after this, an ultrasound-guided
approach was introduced by Hebbard [6].
The aim of the block is to deposit local anesthetic in
the plane between the transversus abdominis and internal
oblique muscles and block spinal nerves T6–L1, which
innervate the abdominal wall. However, the degree of
sensory blockade has not been assessed in randomized
trials and assessed inconsistently in observational studies
[5-7]. A commonly identified deficiency in the literature is
the lack of consensus regarding the optimal procedure-
specific volumes and local anesthetic concentrations
for lumbar TAP blocks. It is not yet clear whether the
ultrasound-guided TAP block, as described by Hebbard
[6], is sufficient for surgical procedures located at both the
supra- and the infraumbilical levels, or whether upper
abdominal procedures need an additional subcostal TAP
block [8].
The primary objective of this study was to assess the
feasibility of conducting a full-scale trial of similar design.
Feasibility was measured as 1) whether the target patients
could be successfully recruited and followed to the end of
the study and 2) whether the designed interventions were
safe. A secondary objective was to gather basic clinical
and statistical information on the differences in TAP block
height to inform a sample size calculation for a full study.
The clinical objective for this study was to determine the
dermatomal sensory block distribution in adult female
patients undergoing total abdominal hysterectomy fol-
lowing the injection of three different local anesthetic
volumes used with ultrasound-guided bilateral midaxillary
TAP blocks. We hypothesized that greater local anesthetic
volumes (i.e., 30 and 40 ml) would lead to more cephalad
dermatomal blockade.
Methods
Design and eligibility criteria
This pilot trial was a prospective, randomized controlled,
double-blinded study. The study was approved by the St.
Joseph’s Healthcare Hamilton Research Ethics Board, and
written informed consent was obtained from all subjects.
Patients undergoing total abdominal hysterectomy via
Pfannenstiel incision for non-malignant pathology, be-
tween the ages of 18 and 70 years with no history of
chronic opioid use or abdominal surgery, were includedin the study. Patients with a history of coagulopathy, local
or systemic infection, local anesthetic allergy, or body
mass index greater than 35 kg/m2 were excluded.
Randomization
Subjects were randomized to one of three lumbar TAP
block local anesthetic groups. Group A received 20 ml
of 0.5% ropivacaine per side, group B 30 ml of 0.33%
ropivacaine per side, and group C 40 ml of 0.25% ropiva-
caine per side. Randomization was achieved with 1:1:1
allocation ratio and took place intraoperatively with con-
cealment by our hospital pharmacy until study comple-
tion. The patients, anesthesiologists, and post-block assessor
were blinded to group allocation.
Treatment procedures
All subjects underwent a standardized general anesthetic.
Induction was performed using 2 mcg/kg of fentanyl,
1–2 mg/kg of propofol, and 0.6 mg/kg of rocuronium.
Maintenance was achieved with sevoflurane at 1 minimal
alveolar concentration (MAC), rocuronium as needed to
keep two twitches using a nerve stimulator, and fentanyl 1
mcg/kg to keep systolic blood pressure within 20% of
baseline. Thirty minutes before the end of surgery, mor-
phine 3 mg and ondansetron 4 mg were administered to
each patient.
Upon surgical completion, bilateral ultrasound-guided
lumbar TAP blocks were performed while the patient was
still under anesthesia and intubated. Three anesthesiolo-
gists, each skilled in lumbar TAP blockade, performed
all blocks. Under sterile technique, a 12-MHz linear US
transducer (GE Logiq E, Wisconsin, USA) was placed
in a transverse orientation between the inferior costal
margin and iliac crest in the midaxillary line. An 80 mm,
22-gauge EchoStim® needle (Benlan Inc., Oakville, ON,
Canada) was advanced using an in-plane approach from
medial to lateral and placed between the internal oblique
and transversus abdominis muscles. Under real-time
visualization, the randomized volume of ropivacaine was
slowly injected followed by appropriate plane hydro-
dissection.
The syringes containing the pre-mixed local anesthetics
were placed in opaque containers by the hospital phar-
macy and delivered to the operating room during the
procedure. An anesthesia assistant aided in each TAP
block and was responsible for confirming negative as-
piration prior to injection of the local anesthetic. In this
way, the anesthesiologist remained blinded to group al-
location. The identical procedure was then performed
on the contralateral side. The patient was extubated and
transferred to the post-anesthetic care unit (PACU). All
patients received a multimodal approach to pain man-
agement, including patient-controlled analgesia (PCA)
opioid (morphine 1 mg IV q7min or hydromorphone
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q6h for 48 h), and ketorolac (10 mg IV q6h for 48 h).
No neuromodulators or long-acting opioids were prescribed.
Perioperative data collection was performed by a re-
search assistant not involved with patient care. Patients
were assessed at 2, 6, 12, 24, and 48 h post-block. Numer-
ous outcome measures, including sensory blockade, PCA
opioid use, pain scores at rest and with knee flexion, inci-
dence of nausea and vomiting, and sedation scores were
assessed at each time interval. Overall patient satisfaction
and time to PACU discharge were assessed by chart re-
view at 48 h.
Outcomes
The primary outcomes of this study were feasibility mea-
surements. The feasibility of carrying a similar study de-
sign to a full-scale RCT was assessed in three respects:
recruitment, follow-up, and safety. The success of recruit-
ment was measured as eligibility rate (the number of
eligible patients over the number of screened patients),
recruitment rate (the number of recruited patients over
the number of eligible patients), and the length of re-
cruitment. The success of patient follow-up was reported
as follow-up rate (the number of patients followed to
the end of study period over the number of patients
who underwent the intervention) and full data collection
rate (the number of patients with all clinical endpoints
collected over the number of patients who underwent
the intervention). Patient safety was monitored by the
incidence of pre-defined clinical adverse events (local
anesthetic toxicity, bleeding, visceral injury).
Beyond these feasibility measurements, clinical informa-
tion was collected as secondary outcomes for the purposes
of gathering essential clinical and statistical information
for future studies. Dermatomal block distribution, the pri-
mary clinical focus, was evaluated by loss of sensation to
ice and pin prick. This was performed with a standard
dermatomal map drawn onto each patient’s abdomen at
the first post-block assessment. Each dermatome was
assessed at four locations (right midclavicular, right ster-
nal, left sternal, and left midclavicular), moving from T6
down to L1. Sensory change was compared to sensation
at the C3/C4 dermatomes, with any reduced sensation
counted as a blocked dermatome. Block failure rate was
defined as the lack of any sensory block at all-time
points following the TAP block.
Patient pain scores at rest and with knee flexion were
assessed using the visual analog scale, with patients indi-
cating their pain level on a continuous line between “no
pain” (0) and “the worst pain of my life” (10). Postopera-
tive opioid use was assessed by converting all opioids to
intravenous morphine equivalents. Hydromorphone was
converted to morphine by multiplying by a factor of five.
Postoperative nausea and vomiting (PONV) was assessedusing a four-point scale. A score of 0 indicated no nausea
or vomiting, 1 mild (no treatment required), 2 moderate
(treatment required and effective), and 3 severe (treatment
required but not effective). Overall patient satisfaction was
assessed by a five-point Likert score at 48 h. Time to
PACU discharge was determined by chart review at 48 h.
Sample size and statistical methods
As this pilot trial was designed mainly for the purposes
of feasibility assessment, no formal sample size calcula-
tion was performed: the decision on size was primarily
based on constraints of time and financial burden. The
primary feasibility objectives were to successfully imple-
ment the study design while recruiting a target sample
of 30 patients over a 6–8-month period and achieving
more than 90% follow-up at 48 h. The feasibility outcomes
were reported descriptively and narratively. For the clin-
ical endpoints, only descriptive statistics, mean (standard
deviation) for continuous outcomes and raw count (%) for
categorical outcomes, were reported. Due to the nature of
pilot designs, we chose not to conduct any informative
statistical tests on the collected data. Statistical analyses
were performed using Stata 10.2 (StataCorp LP, College
Station, TX).
Results
The primary outcome of this pilot study was feasibility
assessment including recruitment, follow-up, and patient
safety. The details of the recruitment and follow-up of
the study are shown in Figure 1. Recruitment occurred
between March and November, 2011. One hundred thirty
patients were initially screened. The eligibility rate was
46% (60/130). Among the 60 eligible patients, we obtained
initial consent from 31 (recruitment rate: 52%) patients
who were then randomized into three intervention arms.
Among the 31 randomized patients, it was noted that one
patient had failed to give signed consent, despite giving
verbal consent, and one patient was found to have had
protocol violation: these patients were removed from
the intervention and their clinical data was not collected
thereafter. A total of 58 TAP blocks were performed.
Eighteen patients completed the full 48-h postoperative
assessment. Among the patients who were not available
for 48-h assessment, ten were discharged from hospital
before 48 h and therefore were not considered as lost to
follow-up: one patient who refused assessment at 48 h
was considered as lost to follow-up (lost to follow-up rate,
3%). The time used to complete recruitment was 8 months.
Regarding patient safety, no clinical adverse events were
reported.
Baseline patient characteristics for the three interven-
tion groups are reported in Table 1.
There were no block failures in any patient. The mean




• Did not meet inclusion criteria 
(n=63)





Ropivacaine 0.33% 30ml (n=10)
Received intervention (n=10)
Did not receive allocated intervention 
(n=0)
Allocated to intervention:
Ropivacaine 0.5% 20ml (n=10)
Received intervention (n=9)
Did not receive allocated intervention 
(did not give written consent) (n=1)
Allocated to intervention:
Ropivacaine 0.25% 40ml (n=11)
Received intervention (n=10)
Did not receive allocated intervention 
(protocol violation) (n=1)
Analyzed (n=9)
Excluded from analysis (n=0)
Analyzed (n=10)
Excluded from analysis (n= 0)
Analyzed (n=10)
Excluded from analysis (n=0)
Figure 1 Consort flow study diagram.
Forero et al. Pilot and Feasibility Studies  (2015) 1:10 Page 4 of 8was T8 (Figure 2). The mean maximal dermatome block
was similar between 2 and 12 h. However, by 48 h, the
highest mean sensory block dropped nearly one dermato-
mal level among all blocks. Figure 3 illustrates the distribu-
tion of the median highest and lowest blocks over time.
Figure 4 shows the change in sensory block at the ster-
num for each group, comparing “early block” (2–6 h) toTable 1 Demographic characteristics of patients in the differe
Patient characteristics 20 ml 0.5% ropivacaine (n = 9) 30 m
Age (years) 43.1 (5.5) 44.1
Weight (kg) 73.7 (16.5) 64.6
Height (cm) 160.3 (6.7) 160.6
BMI (kg/m2) 28.5 (5) 24.7
Data presented as mean (SD).“late block” (24–48 h). The presence of a dermatomal
sensory block in more than 80% of the patients was con-
sidered significant. In group A, a sensory block between
T9 and L1 was seen at each of the five time points. In
group B, a T9–L1 sensory block was initially present but
regressed to T10–T12 beyond 24 h. In group C, a T9–T12
block was achieved during the first 12 h, but only T12nt treatment groups












Figure 2 Mean maximal dermatomal blockade among the three groups over time.
Time post-block (hours)
Figure 3 Median highest and lowest blocked dermatomes between the three groups.


















Local anesthetic volume (ml)
Figure 4 Dermatomal block behavior over time as a function of local anesthetic volume.
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dictably among the three groups less than one third of the
time.
Midclavicular sensory block was less prominent than
sternal blockade in groups A and B, with the same derma-
tome being blocked approximately 20% less often in the
former. In contrast, group C had a similar percentage of
dermatomes blocked in both locations. The behavior of
the midclavicular blocks mirrored their sternal counter-
parts over time in all groups. A mean maximal block
above T9 was not attained at the midclavicular level at
any time point in any group.
The time to PACU discharge, along with other second-
ary clinical outcomes, is summarized in Table 2. There
was a 50-min longer PACU stay in group B compared to
group A (49.76, 4.72 to 94.8). Patient satisfaction was simi-
lar between groups. Total postoperative opioid use in group
A was slightly higher. Group B used 26 mg less morphine
than group A (−26.1, −75.9 to 23.8), while group C used
23 mg less than group A (−22.7, −74.72 to 29.34). WithTable 2 Comparison of secondary outcome measures of patie
Outcome measure 20 ml 0.5% ropivacaine (n = 9) 3
Total PCA morphine use (mg) 65.9 (63) 3
Time in PACU (min) 138.4 (38) 1
Satisfaction score 4.3 (3.5) 2
Pain score at rest (at 2 h) 6.1 (2.4) 5
Pain score with knee flexion (at 2 h) 6.7 (2.1) 5
PONV (at 2 h)a 6 (66.7) 3
Sedation (at 2 h)a 6 (66.7) 8
Data presented as mean (SD) for continuous and count (%) for dichotomous variabregard to pain scores at rest and with knee flexion, no
meaningful difference was observed between the groups. At
rest, groups B and C experienced less pain than group A
(−0.4, −1.79 to 1, and −0.67, −2.01 to 0.79, respectively).
However, in all three groups, less pain appears to have been
experienced between 6 and 48 h when compared to 2 h
(−2.5, −3.77 to −1.22). No clinical difference existed be-
tween nausea scores at any time point. Three patients in
group A, one in group B, and two in group C reported se-
vere nausea at one time point during assessment. Likewise,
the sedation levels were similar.
Discussion
We enrolled total abdominal hysterectomy patients into
a pilot RCT that assessed the feasibility of a trial that used
three volumes of local anesthetic to achieve different block
heights with a TAP block. We achieved our feasibility tar-
gets in that we recruited 31 patients over an 8-month
period. Our recruitment rate was reasonably high and the
loss to follow-up rate was quite low. It seems that patientsnts in the three treatment groups
0 ml 0.33% ropivacaine (n = 10) 40 ml 0.25% ropivacaine (n = 10)
9.8 (25.2) 43.2 (36.9)
88.2 (54) 154.6 (43)
.6 (2.5) 1.8 (1.3)
.3 (2.4) 5.4 (2.3)
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type of trial. Further, with no serious clinical adverse
events observed and only one patient dropping out of the
study before completion for unveiled reasons, we believe
that it is safe to conduct future RCTs under similar inter-
ventions. However, given our center had a mean recruit-
ment rate of 3.9 patients per month, a definitive trial
would take over 7 years at our center. To complete a de-
finitive trial, a multicentre trial would be necessary such
that it could be completed in a reasonable period of time.
One potential setback was that of patients being dis-
charged prior to completing the 48-h study period. In
designing a future study, perhaps the study period can
be reduced to the average length of hospital stay among
the studied patient population.
The preliminary clinical finding of this study is the lack
of volume effect in the cephalad spread of the midaxillary
lumbar TAP block. Higher volumes of equal local
anesthetic dose did not result in higher blockade nor
did they translate to better analgesia outcomes or less
opioid side effects. The strength of our study is that it
was randomized and blinded and the follow-up was
mostly complete. One could argue that our findings
are limited by the fact that our methods varied both
volume and concentration of local anesthetic, with the
smallest volume group receiving the highest concentration
of solution and the largest volume group receiving the
least concentrated solution. Hence, the lack of volume ef-
fect could have been partially due to the effect of variable
local anesthetic concentration. Other limitations of this
study include the lack of weight-based local anesthetic
dosing, a small sample size, and a BMI cutoff of 35 kg/m2,
which limits generalizability.
Few studies have explored block distribution following
TAP block. An observational trial by Lee et al. [9]
assessed block distribution after the injection of 20 ml
0.5% ropivacaine either by posterior or subcostal ap-
proaches. The posterior approach led to T10–T12
blockade, while the subcostal to T9–T11 blockade. The
highest dermatomes reached for the posterior and sub-
costal TAP blocks were T10 and T8, respectively. Our
findings indicate that T9 and L1 are blocked more fre-
quently than reported by Lee [9] and by Carney et al.
[10] MRI contrast study, particularly in group A. A ca-
daver study by Rozen et al. [11] showed that nerves in
the anterior axillary line have variable segmental origin
from T9–L1, and perhaps midaxillary injection in our study
allowed for more frequent blockade. Another cadaver study
by Tran et al. [12] failed to show T9 staining, possibly due
to postmortem contraction of fascial planes. Paravertebral
spread may also play a role in achieving midthoracic
blockade. Carney et al. [10] showed that contrast spreads
to thoracic paravertebral spaces even after midaxillary
injection.Taken together, our results suggest that the 20 ml group
achieved a consistent and lasting block that involved T9
to L1 dermatomes. Higher volumes of more dilute local
anesthetic failed to result in longer lasting cephalad spread
and were more prone to miss L1. In all groups, spread to
T6 was achieved in a small number of patients, but
consistent high thoracic blockade cannot be relied upon
following a midaxillary block.
All three groups experienced some sensory blockade
at 48 h, a seemingly long time after a single-shot block.
While 48-h dermatomal blockade has not been assessed
in previous studies, Carney et al. [13] showed superior
analgesia at 48 h following TAP block with ropivacaine
versus placebo block for total abdominal hysterectomies.
It has been proposed that such prolonged analgesic bene-
fit may be related to the poor vascularity of the TAP and
therefore delayed local anesthetic uptake [13]. Several of
our patients were discharged prior to 48 h and it is not
known if there is additional dermatomal blockade beyond
this time point.
With regards to other secondary outcomes, despite the
presence of dermatomal sensory block, morphine con-
sumption in all groups was higher than that reported in
previous landmark-based TAP studies [3,4,13], particu-
larly in group A (65.9 ± 63 mg). Carney et al. [13] found
48 h morphine consumption to be 27 ± 20 mg following
TAP block. It is possible that this difference is due to dif-
ferences in block technique. A recent systematic review
revealed a trend towards prolonged analgesia following
TAP block more posteriorly in the triangle of Petit [14].
A block in the triangle of Petit may block branches of
T6–L1 nerves before they anastomose. Unfortunately,
the above landmark-based studies which had reduced
opioid consumption did not perform sensory block as-
sessments, and it is therefore unknown if reduced opi-
oid consumption was the product of clinically better
blockade. TAP blocks address somatic pain, leaving the
visceral component of pain intact. Griffiths et al. failed
to show an analgesic benefit or opioid-sparing effect with
TAP blocks for gynecological cancer surgery, possibly
due to more extensive intraoperative visceral manipula-
tion [15]. In our study, despite having somatic blockade,
visceral pain likely contributed to significant morphine
requirements. Assessing the nature of the patient’s pain
would help to answer this question.
Conclusions
In conclusion, this pilot study demonstrates that the study
design is suitable and safe to be carried to a full-scale RCT
but would likely require a multicentre approach. The
preliminary clinical results showed that increasing the
volume, while maintaining a constant dose of local
anesthetic, does not appear to significantly extend the
height of dermatomal blockade following single-shot
Forero et al. Pilot and Feasibility Studies  (2015) 1:10 Page 8 of 8midaxillary TAP block. The commonly utilized volume
of 20 ml of more concentrated local anesthetic (in this
case 0.5% ropivacaine) per side does appear to produce
a consistent and long lasting low thoracic/high lumbar
blockade. However, this finding needs to be confirmed
in larger studies. Researchers interested in joining a fu-
ture multicentre trial should contact the authors.
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